DE VIVO, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 1.152
EU - Europa 918
AS - Asia 282
AF - Africa 68
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.424
Nazione #
US - Stati Uniti d'America 1.152
GB - Regno Unito 263
SE - Svezia 174
DE - Germania 116
VN - Vietnam 105
CN - Cina 95
IT - Italia 95
UA - Ucraina 55
IN - India 46
IE - Irlanda 43
CH - Svizzera 38
TG - Togo 35
BE - Belgio 32
FR - Francia 31
RU - Federazione Russa 30
EE - Estonia 20
JO - Giordania 20
ZA - Sudafrica 17
FI - Finlandia 10
CI - Costa d'Avorio 8
GR - Grecia 6
IR - Iran 6
LB - Libano 6
NG - Nigeria 3
RO - Romania 3
SC - Seychelles 3
BR - Brasile 2
HK - Hong Kong 2
JP - Giappone 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
HR - Croazia 1
NL - Olanda 1
Totale 2.424
Città #
Southend 235
Fairfield 169
Chandler 139
Woodbridge 94
Ann Arbor 89
Houston 87
Seattle 79
Ashburn 75
Wilmington 66
Princeton 44
Dublin 43
Cambridge 42
Bern 36
Jacksonville 35
Lomé 35
Brussels 32
Dong Ket 32
Nanjing 23
Turin 23
Padova 21
Westminster 21
Amman 20
Berlin 15
Bremen 13
Changsha 9
Helsinki 9
Saint Petersburg 9
San Diego 9
Abidjan 8
Boardman 8
Jinan 8
Hebei 7
Shenyang 7
Bologna 6
Florence 6
Milan 6
Nanchang 6
Beijing 5
Mülheim 5
Zhengzhou 5
Dearborn 4
Des Moines 4
Haikou 4
Jiaxing 4
Zanjan 4
Abeokuta 3
Frankfurt am Main 3
Mahé 3
Norwalk 3
Verona 3
Athens 2
Boydton 2
Falls Church 2
Kuban 2
Kunming 2
Lanzhou 2
London 2
Medford 2
Ningbo 2
Paris 2
Redmond 2
Redwood City 2
San Francisco 2
São Paulo 2
Taiyuan 2
Taizhou 2
Tianjin 2
Tokyo 2
Andover 1
Ardabil 1
Canberra 1
Carol Stream 1
Cupertino 1
Falkenstein 1
Fuzhou 1
Groningen 1
Henderson 1
Hunedoara 1
Kiev 1
Lappeenranta 1
Lausanne 1
Leawood 1
Mehr 1
Montecassiano 1
Moscow 1
Orange 1
Phoenix 1
Rome 1
Sacramento 1
Saint Quentin 1
San Venanzo 1
Stockholm 1
Tappahannock 1
Walnut 1
Totale 1.678
Nome #
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 207
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 179
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 158
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 150
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 148
Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. 140
BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study. 131
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 131
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 114
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 107
Intestinal microflora and digestive toxicity of irinotecan in mice. 101
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 97
Impact of surgery on the development of duodenal cancer in patients with familial adenomatous polyposis. 97
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 95
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 90
null 81
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 78
null 76
Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters. 71
THE RISK OF DUODENAL CANCER IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP) 69
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 68
Differences among young adults, adults and elderly chronic myeloid leukemia patients 47
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. 24
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 15
Erratum: Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia (Blood (2013) 121:26 (5138-5144)) 11
Totale 2.485
Categoria #
all - tutte 4.296
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.296


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019146 0 0 1 20 3 22 9 7 14 28 20 22
2019/2020703 87 20 7 48 82 78 82 95 92 46 32 34
2020/2021340 71 26 8 23 7 16 3 16 24 25 20 101
2021/2022509 56 12 27 67 41 22 5 31 16 38 113 81
2022/2023655 66 103 38 70 36 46 21 30 109 16 63 57
2023/202447 12 24 11 0 0 0 0 0 0 0 0 0
Totale 2.485